Smith & Nephew plc (LON:SN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,077.29 ($13.97) and traded as high as GBX 1,125.50 ($14.60). Smith & Nephew shares last traded at GBX 1,088 ($14.11), with a volume of 3,671,923 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank reiterated a "buy" rating and issued a £145 ($188.04) price objective on shares of Smith & Nephew in a report on Monday, August 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of GBX 3,956.20 ($51.31).
Read Our Latest Report on Smith & Nephew
Smith & Nephew Trading Up 1.4 %
The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The business has a 50-day simple moving average of GBX 1,150.07 and a 200-day simple moving average of GBX 1,077.29. The company has a market cap of £9.62 billion, a PE ratio of 4,085.19, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.
Smith & Nephew Cuts Dividend
The firm also recently announced a dividend, which will be paid on Friday, November 8th. Investors of record on Thursday, October 3rd will be paid a dividend of $0.14 per share. This represents a yield of 1%. The ex-dividend date is Thursday, October 3rd. Smith & Nephew's payout ratio is currently 10,740.74%.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
